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Human exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and chlorinated analogs commonly
results in pathological changes in the skin and its appendages characterized by thickening ofthe epidermis
(acanthosis), hyperkeratosis and squamous metaplasia of the epithelial lining of the sebaceous glands.
Acneform lesions (chloracne) develop as hair follicles dilate and fill with keratin and sebaceous glands
become cystic. In animal models it has been found that the chloracneogenic potential of the halogenated
aromatic compounds examined corresponds with the relative affinity of these same compounds for the
cytosolic TCDD receptor. This receptorcontrolsthe coordinate expression ofanumber ofinducible enzyme
activities and in certain cell targets can alter normal programs ofproliferation and differentiation. In this
report we describe some of our ongoing studies on the mechanisms of action of TCDD in normal human
epidermal cells and squamous cell carcinoma (SCC) lines. These systems permit detailed investigation of
the molecular and biochemical events underlying pathologic changes in the skin and offer the potential of
establishing a risk assessment model for halogenated aromatic compounds by using human target cells.
Introduction
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is the
prototype for the halogenated aromatic compounds
including the polychlorinated biphenyls (PCBs) (1,2).4
Studies in animals indicate that TCDD and isosteric
analogs act through a common receptor to produce
characteristicpatternsoftoxicandbiochemical responses
(2,3). Toxic responses commonly observed in most
animal species include a slow wasting syndrome,
terator,enesis, andthymicatrophy(4-6). Species-specific
responses include hepatoxicity, edema of the pericar-
dium, hyperkeratosis and chloracne, and at high doses,
acute lethality (1,2,7-9).
A number of clinical abnormalities have been re-
ported in individuals exposed to various halogenated
aromatic compounds. Chloracne is one of the most
sensitive andwidespread responses observed inhumans
(10,11). Other symptoms include weight loss, impaired
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liver function, hepatic porphyria, general malaise, and
peripheral neuropathies (12). These are discussed in
greater detail elsewhere in this volume (see section on
clinical aspects of human toxicity). This report focuses
on model cell culture systems formechanistic studies on
the toxicity of chlorinated aromatic compounds to the
human epidermis and the potential value of these
systems in risk assessment.
TCDD is the most potent ofthe halogenated aromatic
compounds, a property presumably associated with its
relative inertness to biological and chemical degrada-
tion (13) and its high affinity for the cytosolic receptor
(14). Other members of this class which are more
readily metabolized, such as the PCBs, possess similar
affinities for the cytosolic receptor measured in vitro
(15), but vary widely in their toxic potency (1,3),
indicating the importance of considering both pharma-
cokinetic and mechanistic studies in estimating human
health risks.
Ah Locus: Role in Mediating
Toxicity of Chlorinated Aromatic
Compounds
In certain inbred murine strains, the induction by
TCDD of cytochrome(s) P1-450 and several associatedGREENLEE ET AL.
monooxygenase activities, including aryl hydrocarbon
hydroxylase (AHH) and 7-ethoxycoumarin 0-deethy-
lase (ECOD), is regulated by a single genetic locus (des-
ignated theAh locus) and its putative gene product, the
TCDD receptor protein (14,16,17). In these same mu-
rine strains, TCDD-induced thymic atrophy and cleft
palate formation segregate with the Ah locus (18). Re-
cent investigations have also shown that TCDD pro-
duces epidermal hyperplasia (19) and promotes skin
papillomas (20) in hairless mice bearing the recessive
mutation hrlhr. Further, the data indicate that TCDD-
induced epidermal hyperplasia requires interaction be-
tween two regulatory gene loci, Ah and hr (19). Based
on these and other findings (2,18-20), it has been pos-
tulated that the murine Ah locus, either singly or in
concert with other regulatory genes, controls at least
two distinct pleiotropic responses: a limited, but widely
expressed gene battery which includes the structural
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FIGURE 1. Fractional log dose-response curves for the induction of
ECOD activity in human SCC cell lines by TCDD: (0) SCC-9; (@)
SCC-13; (a) SCC-15; (u) SCC-12F; (A) SCC-4. SCC cells were
seeded at a density of 104 cells /60 mm plastic culture dish in 4
mL of growth medium (Dulbecco's modified Eagle's medium sup-
plemented with 5% fetal bovine serum and 100 ,ug/mL each of
penicillin and streptomycin; this is the growth medium used in all
the experiments with SCC cells described in this report) in the
presence of a feeder layer of 10 lethally irradiated murine 3T3
fibroblasts. The cultures were incubated at 37°C in a humidified
atmosphere of5% C02:95% air, andthegrowthmedium waschanged
every third day. At confluence, growth medium containing the
indicated concentration of TCDD was added. After 2 days the
cultures were washed three timeswith0.02% EDTA inphosphate-
buffered saline and ECOD activity was assayed as described pre-
viously (25,41). Fractional responses were calculated by equating
maximally induced activity to 1.0 and control activity to 0. Taken
from Hudson et al. (25), reproduced with permission of the
publisher.
as skin and thymus, a second gene battery regulating
cell proliferation and differentiation (3).
Evidence for the Ah Locus
in Human Cells
The presence of the Ah locus in human cells, sug-
gested by findings on the induction ofAHH activity in
cultured mitogen-activated lymphocytes (21), has not
been conclusively established. Studies on the induction
ofAHH activity in cultured lymphocytes (22) and mon-
ocytes (23) from monozygotic and dizygotic twins con-
firm a heritable component, but are not able to
distinguish between a monogenic or polygenic mode of
inheritance (22). Chromosome mapping in mouse-hu-
man cell hybrids suggests that either the structural or
the regulatory genes for the induction ofAHH activity
are located on human chromosome 2; however, partic-
ipation of mouse genes in the observed response is not
ruled out (24).
We examined the responsiveness of cultured human
squamous cell carcinoma (SCC) lines derived from
tumors of the epidermis and tongue to TCDD by
measuring the induction ofECOD activity (Fig. 1) (25).
In four of the SCC lines, the EC50 (concentration
required to elicit 50% of the maximal response) is
approximately 1i0 M, whereas in one line the EC50 is
10-10 M. In each ofthe less sensitive lines a concentra-
tion of10-10 M TCDD elicits lessthan 5% ofthe maximal
enzyme activity. Specific binding ofradiolabeled TCDD
is detected in the cytosol fraction from all the SCC lines
(Table 1) and therelative amount ofreceptorin each line
correlates with maximally induced ECOD activity (25).
These dataindicate that human cell lines derived from a
target tissue for TCDD toxicity contain the TCDD
receptor and show differential sensitivity to TCDD
1 -7 Table 1. Specific binding of [3H]ITCDD to cytosol fractions from
SCC lines.
Relative response
Specific binding, Specific ECOD
Cell line fmole/mg cytosol proteina bindingb activityc
SCC-9 9.2 (0.6) 5.3 5.2
SCC-15 6.1 (1.8) 3.5 2.2
SCC-12F 1.8 (0.3) 1.0 1.0
aSpecific binding was measured by sucrose-density gradient analy-
sis as described previously (25). Values shown represent the average
from two experiments. The range is given in parentheses. The total
amountofprotein added tothegradientrangedbetween 4 to 5mgand
the ratio of total to nonspecific binding was approximately 5 to 1.
Single determinations on lines SCC-13 and SCC-4 gave values of 8.5
and 5.8 fmole/mg cytosol protein, respectively Taken from Hudson et
al. (25).
bCalculated from the average values for the specific binding in each
line and normalized with respect to the value obtained for line
SCC-12F.
cDetermined from the maximally induced activities given in Fig. 3
and normalized with respect to the value obtained for line SCC-12F.
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analogous to the murine strain differences in sensitivity
regulated by the Ah locus (25).
Model Cell Culture Systems to
Study Mechanisms of Epidermal
Toxicity
The skin lesions produced by TCDD and halogenated
isostereomers are typified by thickening of the epider-
mis(acanthosis), hyperkeratosis andsquamousmetapla-
sia ofthe epithelial lining ofthe sebaceous glands (4,8).
Acneform lesions develop as hair follicles dilate and
become filled with keratinaceous material and seba-
ceous glands become cystic (12). In animal models the
available data on structure-activity relationships indi-
cate that the chloracneogenic potential of halogenated
aromatic compounds corresponds with the capacity of
these same compounds to bind to the TCDD receptor
and evoke biochemical and toxic responses in other
tissues (2,18,19,26,27). It would appear that the same
structure-activity relationship can be used to predict
skin toxicity in humans (2,28).
Two epithelial keratinizing cell types have been suc-
cessfully serially cultivated by using lethally irradiated
3T3 murine fibroblast feeder layers; XB cells, a cell line
derived from a mouse teratoma (29); and normal human
epidermal cells, usually obtained fromneonatalforeskin
(30). Monoclonal colonies consisting of multiple cell
layers appear in culture. Within each colony, proliferat-
ing cells are confined to the basal layer. As cells migrate
to upper layers, they lose their capacity to divide and
begin the process of terminal differentiation. This is
marked by an increase in cell size, changes in keratin
expression, and the formation of crosslinked cornified
envelopes (31). Flattened and elongated squames are
shed into the media.
TCDD elicits a concentration-dependent keratiniza-
tion response in cultured murine XB cells (32). It was
suggested that the keratinization response inthese cells
was mediated by the TCDD receptor based on dose-
response parameters and structure-activity relation-
ship data comparing the potencies of halogenated aro-
matic compounds to induce keratinization in XB cells
with their relative affinities for the TCDD receptor in
murine hepatic cytosol (32).
We have found that TCDD enhances stratification
(Fig. 2) and induces hyperkeratinization (as judged by
the intensity ofRhodanile Blue staining, Fig. 3) in early
passage human epidermal cells (33). These responses to
TCDD are associated with a 30 to 40% inhibition ofboth
basal and epidermal growth factor (EGF)-stimulated
DNA synthesis (33). Similar results were observed in
ahuman SCC line(SCC-12F) withgrowthrequirements
similarto normal epidermal cells (33,34). These findings
are consistent with an enhanced commitment ofprolif-
erating basal cells to terminal differentiation and sug-
gest that these in vitro systems are appropriate models
for hyperkeratinization observed in vivo (4,12).
Regulation of Biochemical
Mediators of Human Epidermal Cell
Proliferation by TCDD
The proliferation and differentiation of epidermal cells
are regulated by several biochemical mediators includ-
ing hydrocortisone, cyclic nucleotides and EGF (31). In
the previous section it was noted that TCDD enhances
keratinization and inhibits EGF-stimulated DNA syn-
thesis in SCC-12F cells. As shown in Figure 4, treat-
ment ofthese cells with TCDD results in a concentration-
dependent decrease in the specific binding of EGF to a
value 40% of control with an EC of 1 nM. Scatchard
analysis ofEGF bindingindicates that TCDD exposure
results in a loss of high affinity (Kd = 2.8 x 10-10 M)
EGF binding sites (34,35).
A structure-activity relationship for down regulation
of EGF binding is shown in Table 2. The response of
cells treated with 2,3,7,8-tetrachloro-dibenzofuran, an
isostereomer of TCDD, is equal to that with TCDD,
whereas no significant alteration in EGF binding occurs
in cells treated with the nonisostereomeric analog,
2,7-dichlorodibenzo-p-dioxin. The observed stereospeci-
ficity (Table 2) and potency (EC50 = 1 nM, Fig. 4)
suggest that the down regulation of EGF receptors in
SCC-12F cells by TCDD is mediated by the TCDD
receptor.
The kinetics ofinhibition ofEGF bindingin SCC-12F
cells by TCDD and benzo(a)pyrene differ (Table 3).
Maximum inhibition induced by benzo(a)pyrene, an
agent which inhibits EGF binding in C3H1OT1/2 cells
(36) and hepatoma cell lines (37), occurs within 24 hr.
with 90% recovery by48hr. Incontrast, TCDDrequires
72hrtoproduce maximuminhibition, and norecoveryis
observed 10 days after removal of TCDD from the
culture medium (34,35). TCDD produces hyperkeratini-
zation in SCC-12F cells (33) and is characterized by its
abilitytoproduce aprolonged decrease in EGF binding.




fmole/mg proteinb Binding, % of control
DMSO (0.1%) 8.92 ± 0.93 100
2,7-DpD (1076 M) 8.41 ± 0.67 94
TCDBF (3 x 107 M) 2.97 ± 0.21 33
TCDD (10e M) 3.38 ± 0.52 38
aConfluent cultures of SCC-12F cells were treated with the
indicated compounds or solvent vehicle for 72 hr prior to the mea-
surement of EGF specific binding (34,35). TCDBF, 2,3,7,8-tetra-
chlorodibenzofuran; 2,7-DpD, 2,7-dichlorodibenzo-p-dioxin. Adapted
from Hudson et al. (34,35).
bValues shown are the means (± SE) of determinations on tripli-
cate cultures normalized with respect to total protein.
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FIGURE 2. Enhanced stratification in colonies of normal human epidermal cells treated with TCDD: (A) Control, x40; (B) TCDD, x40,
arrows indicate areas of enhanced stratification.
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FIGURE 2 (cont'd). (C) TCDD, x 100; area shown is that indicated by the arrow to the left in B; (D) TCDD, x 100; same field as in C but
focused on a more superficial cell layer. Note the loosely adherent squames, which lack discernible intracellular organelles, as indicated by
the arrowheads. Cells were plated at a density of 5 x 103 cells/60 mm plastic culture dish and were grown as described in the legend to
Fig. 1 except that the growth medium used for normal epidermal cells was 75% Dulbecco's modified Eagle's medium: 25% Ham's F12
medium supplemented with 5% fetal bovine serum, 10 ng/mL epidermal growth factor, 0.4 ,ug/mL hydrocortisone, 10 ng/mL cholera toxin,
and 100 ,ug/mL each ofpenicillin and streptomycin. Two days later, growth medium containing TCDD (10 nM) or solvent vehicle (0.1% p-
dioxane) was added. The medium was replaced every 3-4 days with fresh growth medium containing the appropriate additions and the




FIGURE 3. TCDD-induced hyperkeratinization in cultured normal human epidermal cells. Cells were plated at a density of3 x 105 and were
grown to confluence using the methods described in the legends to Figs. 1 and 2. The confluent cultures were treated with TCDD (10 nM)
or solvent vehicle (0.1% p-dioxane) and maintained in culture for 2 weeks. At the end of the treatment period, the cultures were fixed and
stained with Rhodanile Blue (30). The intensity of staining is a measure of the degree of keratinization.
Benzo(a)pyrene, which binds to the cytosolic TCDD
receptor, but-to ourknowledge has notbeen reported to
produce hyprkeratinization in vivo, produces a tran-
sient inhibition of EGF binding. These data comparing
the actions ofTCDD and benzo(a)pyrene suggest that a
sustained refractoriness to growth factors such as EGF
may be important in the expression of hyperkeratini-
zation.
Several lines ofevidence indicate that enhanced pro-
liferation of human epidermal cells is associated with
increased concentrations of intracellular cyclic AMP
(cAMP) (38). In initial studies we have examined the
actions ofTCDD on the regulation ofadenylate cyclase
activity in human SCC lines with different growth re-
sponses to TCDD. Under appropriate culture condi-
tions, treatment of line SCC-9 with TCDD enhances
colony expansion (39), whereas in line SCC-12F, TCDD
inhibits colony expansion (39). In SCC-9 cells TCDD
appears-to act through a unique membrane receptor
mechanism to stimulate adenylate cyclase activity nearly
2-fold (40). The mechanisms forthe modulation ofaden-
ylatecyclaseactivitybyTCDD arenotknown; however,
preliminaryevidence suggeststhatTCDD mayalterthe
responsiveness of the cyclase system to several well-
characterized homone activators (M. J. Young, personal
communication).
Summary and Conclusions
Treatment ofearly passage normal epidermal cells in
culture with TCDD enhances stratification in cell colo-
nies (Fig. 2), increases keratinization in confluent cul-
Table 3. Kinetics of inhibition of EGF specific binding by TODD
and benzo(a)pyrene.
Time, Specific binding,








aConfluent cultures of SCC-12F cells were treated with solvent
vehicle (DMSO, 0.1%), TCDD, or benzo(a)pyrene for the times
indicated prior to the determination of EGF specific binding. Values
shown are normalized with respect to total protein. Adapted from
Hudson et al. (34,35).
tures (Fig. 3) and inhibits both basal and EGF-
stimulated DNA synthesis (33,34). These results indi-
cate enhanced cell differentiation in the presence of
TCDD and suggest that TCDD stimulates the commit-
ment of proliferating basal cells to a program of
terminal differentiation.
Using prototype SCC lines which under certain
cultureconditionsdisplayenhancedproliferation(SCC-9)
and differentiation (SCC-12F) inthe presence ofTCDD,
studies were carried out to determine potential bio-
chemical mechanisms for these responses. In SCC-12F
cells, TCDD treatment results in a selective loss ofhigh
affinity EGF receptors (34,35) rendering these cells
refractorytothegrowth stimulatingeffects ofEGF. The
dose-response parameters (Fig. 4) and stereospecificity
(Table 2) of this response suggest that altered regula-









0 0 16-10 109 10O8 10-7
[TCDD] M
FIGURE 4. Concentration-dependent inhibition of EGF specific
binding to SCC-12F cells by TCDD. Confluent cultures of SCC-
12F cells were treated in triplicate with TCDD (1011 to 10-7M) for
72 hr prior to the determination of EGF specific binding. Specific
binding is expressed as a percentage ofthe DMSO control and is
normalized with respect to total protein. The absolute value for
the DMSO control was 8.9 ± 0.6 fmole/mg protein. Taken from
Hudson et al. (34,35).
tion of EGF binding by TCDD is mediated by the
cytosolic receptor shown to be present in all ofthe SCC
lines (Table 1). Under conditions favoring enhanced
proliferation in SCC-9 cells, TCDD does not markedly
inhibit EGF binding (L. G. Hudson, unpublished
observations). TCDD appears to act through a unique
receptor mechanism (40) to stimulate adenylate cyclase
activity nearly 2-fold.
These data suggest that the hyperkeratinization and
hyperplastic responses of epidermal cells to TCDD
result from actions of TCDD at 2 (or more) membrane
sites. Hyperkeratinization may result from the pro-
longed down regulation ofreceptors for growth factors
such as EGF. The inability to respond to growth factors
may then lead to enhanced commitment to terminal
differentiation. Hyperplasia, aresponse commonly seen
in the interfollicular epidermis (12), may result from a
direct and specific activation ofadenylate cyclase activ-
ity by TCDD increasing the intracellular concentration
ofcAMP, a positive mediator ofepidermal cell prolifera-
tion (38). The contrast in the actions ofTCDD in SCC-9
cells versus SCC-12F and normal epidermal cells, as
described above, suggests thattheresponse ofa specific
target cell to TCDD depends on the unique balance of
regulatory mechanisms controlling cell division and
differentiation in that cell.
Cultured Epidermal Cells As a
Risk Assessment Model for
Halogenated Aromatic Compounds
Theresults presented above demonstrate that normal
human epidermal cells and human SCC lines are valu-
able in vitro models for dissecting the biochemical
events responsible for actions ofTCDD onthe prolifera-
tion and differentiation ofhuman target cells to TCDD.
These systems should also prove useful for screening
chloracneogensinquantitativeriskassessment. Parame-
ters such as cell growth rates, DNA synthesis, keratin
expression, crosslinked envelope formation, EGF bind-
ing and stimulation ofadenylate cyclase activity can be
quantitated and are relevant to the spectrum of skin-
associated toxicities resulting from exposure to TCDD.
Further, since the skin is the first site of contact in
many environmental exposure episodes, direct action of
suspect agents on the cultured cells would appear to be
relevant. However, in attempting to quantitate risk it is
also important to consider the combined ability of the
liver and the skin to metabolize and inactivate haloge-
nated compounds. For example, metabolic inactivation
ofcompounds such as the PCBs may greatly reduce the
potential risk for chloracne relative to metabolically
stablecompounds suchasTCDD. Cytochrome(s) P1-450-
associated enzyme activities are inducible in all of the
human SCC lines examined (Fig. 1) and in normal
human epidermal cells (W F. Greenlee, unpublished
observations). Studies are under way to characterize
the biotransformation potential of cultured epidermal
cells. The differences in sensitivity for induction of
ECOD activity by TCDD in SCC lines (Fig. 1) and
differential growth responses to TCDD (25,33), suggest
that these cells have a further relevance in reflecting
genetically determined differences in susceptibility to
TCDD toxicity.
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